Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 10, Number 11—November 2004


Evaluating Human Papillomavirus Vaccination Programs

Al V. Taira*, Christopher P. Neukermans†, and Gillian D. Sanders†‡Comments to Author 
Author affiliations: *Stanford School of Medicine, Stanford, California, USA; †Stanford University, Stanford, California, USA; ‡Duke University, Durham, North Carolina, USA

Main Article

Table 2

Total discounted healthcare costs, total discounted life expectancy in years, and total quality-adjusted discounted lifetime expectancy in years are presented for prevaccination, and for female-only and male + female vaccination scenarios.

Outcome No vaccination HPV-16/18 vaccination
Female-onlya Female + maleb
Cost, $ 40,423 40,667 40,929
Incremental cost, $ 244 261
Life expectancy, y 28.7975 28.8112 28.8117
Incremental life expectancy, d 5.0 0.18
Quality-adjusted life expectancy, y 27.7422 27.7590 27.7596
Incremental quality-adjusted life expectancy, d 6.1 0.21
Incremental cost-effectiveness
$ per life-year 17,802 534,317
$ per quality-adjusted life-year 14,583 442,039
% reduction in lifetime cervical cancer cases 61.8 2.2

aIncremental to no vaccination strategy.
bIncremental to a female-only vaccination strategy.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO